Skip to main content

Table 4 Best overall response

From: A phase II study of sorafenib (BAY 43–9006) in recurrent diffuse large B cell lymphoma: an eastern cooperative oncology group study (E1404)

Response

N

%

Complete Response (CR)

1

7

Stable Disease (SD)

5

36

Progressive Disease (PD)

7

50

Unevaluable *

1

7

  1. * Patient 14012 was unevaluable because he was taken off study after receiving only one cycle of protocol therapy due to adverse events, and never had follow-up disease evaluations.
Back to article page

Journal of Hematology & Oncology

ISSN: 1756-8722

Contact us